Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2017-07-17

Clinical Trial Update: Safety and Efficacy of AIN457 in Noninfectious Uveitis [Phase 2]

View source ↗

Summary

Phase 2 trial assessing the safety and efficacy of AIN457 (secukinumab) for noninfectious uveitis has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • AIN457

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Non-infectious Uveitis | Phase 2 | Status: COMPLETED | Results posted: 2017-07-17